Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01779531
Verified January 2013 by Liao Ning, Guangdong Academy of Medical Sciences. Recruitment status was: Not yet recruiting
: January 30, 2013
Last Update Posted
: January 30, 2013
Guangdong Academy of Medical Sciences
Chinese Anti-Cancer Association
Guangzhou General Hospital of Guangzhou Military Command
Human epidermalgrowth factor receptor-2(HER2) negative Luminal B subtype breast cancer patients are included. After 4 cycles of Capecitabine combined with Docetaxel(XT) protocol neoadjuvant chemotherapy ,those who reach partial response(PR) but not pathological complete response(pCR) are randomly divided into the group treated with XT protocol and the group with Capecitabine combined with Epirubicin and Cyclophosphamide(XEC) protocol ,then compare the disease free survival(DFS) and overall survival(OS) of two subgroup.
Condition or disease
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Individualized treatment of breast cancer has become one of the main directions in the clinical and research areas of breast cancer,and the individualized treatment of the estrogen receptor(ER) positive patients which covered 65% of total cases is of vital importance. Historical research showed that among the ER-positive and HER2-negative breast cancer,Luminal B breast cancer with Ki67>14% is more likely to be benefited from chemotherapy,compared with the Luminal A breast cancer with Ki67<14%. And the results of our previous research showed that, the neoadjuvant XT protocol has more than 17% pCR rate in Luminal B subtype breast cancer.However,to those who didn't reach pCR,we've got no evidence whether switching to Anthracycline-based post operative protocol can benefit them.So that,we sketch out a randomized controlled multicentric phase III clinical trail.HER2 negative Luminal B subtype breast cancer patients are included. After 4 cycles of XT protocol neoadjuvant chemotherapy ,those who reach PR but not pCR are randomly divided into the group treated with XT protocol and the group with XEC protocol ,then compare the DFS and OS of two subgroup.
A Phase III，Randomized ，Multi-center Clinical Trail to Compare the Outcomes of XT and XEC Adjuvant Chemotherapy Protocol in HER-negative Luminal B Breast Cancer Patients Who Reached Pathologic Response After XT Neoadjuvant Chemotherapy
Study Start Date
Estimated Primary Completion Date
Estimated Study Completion Date
Resource links provided by the National Library of Medicine
Disease free survival after adjuvant chemotherapy within five years [ Time Frame: Within 5 years after adjuvant chemotherapy ]
Within 5 years after adjuvant chemotherapy,we should evaluate disease free survival and overall survival rates as the most important outcome measure.
Overall survival after adjuvant chemotherapy within five years [ Time Frame: Within five years after adjuvant chemotherapy ]
Within 5 years after adjuvant chemotherapy,we should evaluate overall survival (OR)rates as the most important outcome measure.
Secondary Outcome Measures
Imaging evaluation after neoadjuvant chemotherapy [ Time Frame: within the 21 days after neoadjuvant chemotherapy ]
After neoadjuvant chemotherapy,we should evaluate the status of patients as progress disease and then use the imaging evaluations as the proofs to plan their next therapeutic schedule or different grouping methods.
Other Outcome Measures:
Baseline evaluation [ Time Frame: before the neoadjuvant chemotherapy ]
Baseline evaluation includes the issues of ECOG PS scores, primary tumor Imaging evaluation, evaluation and reserve of bone marrow and organ function evaluation.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
HER2 negative Luminal B subtype breast cancer patients
Chinese population surgery patients with invasive breast cancer；
Aged between 18 and 70 years old；
The maximum diameter of the primary tumor greater than 1cm；
ECOG score 0-1 points； -Have adequate baseline bone marrow and organ function reserve : absolute neutrophil count ≥ 1500/mm3, platelet count ≥ 8g/dl; the ≥ 100000/mm3 hemoglobin concentration and serum creatinine ≤ 1.5 times the upper limit of normal ; aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal , bilirubin ≤ 1.5 times the upper limit of normal ; left ventricular ejection fraction ( LVEF ) ≥ 50%
Exclusion Criteria: - Non - Chinese population of patients；
Non- invasive cancer patients;
Inflammatory Breast Cancer patients;
Metastatic breast cancer patients;
HER2 positive patients;
No adequateBaseline bone marrow or organ function reserve;
ECOG PS score ≥ 2 points;
Younger than 18 years of age or greater than 70 years old;
Already accepted therapy including chemotherapy , endocrine therapy or targeted therapy before neoadjuvant treatment;
HER2-positive patients with left ventricular ejection fraction less than 55 % can not receiving Herceptin;
Known allergy of docetaxel , capecitabine , epirubicin , ring phosphonamide .